Havas (HAVAS) Q3 2026 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 TU earnings summary
16 Oct, 2026Executive summary
Q3 net revenue was €703m, up 7.2% reported and 2.4% organically; 9M net revenue was €2,065m, up 3.1% reported and 2.5% organically.
North America led Q3 with 7.5% organic growth; Asia Pacific and Africa and Latin America declined.
FY26 organic growth and adjusted EBIT margin guidance were reaffirmed; 2028 targets also remained unchanged.
Financial highlights
Q3 net revenue growth comprised 2.4% organic growth, 3.2% scope and 1.6% FX; reported growth was 7.2%.
9M net revenue growth comprised 2.5% organic growth, 2.5% scope and -1.9% FX; reported growth was 3.1%.
Q3 revenue was €724m, up 6.3% YoY; 9M revenue was €2,140m, up 2.4% reported.
Outlook and guidance
FY26 organic net revenue growth guidance remained 2.0%-3.0%; adjusted EBIT margin guidance remained 13.2%-13.5%, implying 30-60 bps improvement.
2028 adjusted EBIT margin target remained 14.0%-15.0%; dividend payout ratio target remained ~40%.
Q4 market conditions are assumed broadly similar to current conditions; visibility remains limited amid macroeconomic and geopolitical uncertainty.
Bolt-on M&A strategy targets 5-10 acquisitions annually, adding €40m-€50m of net revenue on average at higher profitability than the overall business.
Latest events from Havas
- H1 2026 delivered 2.5% organic growth, 11% EBIT margin, and strong M&A and AI investment.HAVAS
Q2 2026 - Q1 2026 net revenue up 2.5% organically to €638M; guidance and M&A focus reaffirmed.HAVAS
Q1 2026 TU - Organic growth reached 3.1% with higher margins, strong cash flow, and a positive 2026 outlook.HAVAS
Q4 2025 - Q3 organic net revenue grew 3.8%, with raised guidance, margin gains, and AI-driven initiatives.HAVAS
Q3 2025 TU - Strong financials, strategic transformation, and all resolutions approved by large majorities.HAVAS
AGM 2025 Presentation - Q1 2025 net revenue rose 5.2% to €649m, with strong organic growth and guidance reaffirmed.HAVAS
Q1 2025 TU - H1 2025: 2.9% net revenue growth, 8.3% EBIT rise, five acquisitions, and AI rollout.HAVAS
Q2 2025